Released May 9, 2023, after the close
10-Q filed May 9, 2023, 39 days after period end · 0000950170-23-019721
Q1 2023 · 10-Q
Revenue$175.20M$175.20M +64.6% vs Q1 2022+43.3% vs Q4 2022
Net Income-$60.94M-$60.94M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$1.71-$1.71 N/M vs Q1 2022no prior Q4 2022 on file
Gross Profit$110,329,000+41.3%
Operating Income-$59,714,000N/M
Operating Cash Flow-$34,020,000N/M
Free Cash Flowderived-$45,492,000N/M
Margins · derived
Gross margin63.0%−10.4 pt vs Q1 2022
Operating margin-34.1%−31.2 pt vs Q1 2022
Net margin-34.8%−30.6 pt vs Q1 2022
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Revenue | $175.20M | $106.42M | $105.59M | $104.82M |
| Net Income | -$60.94M | -$4.46M | -$5.82M | $25.67M |
| EPS Diluted | -$1.71 | -$0.22 | -$0.30 | $1.32 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR